BSE · 531015
Venmax Drugs & Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2 Cr with net profit ₹-0 Cr — a -0.56% net margin, versus 32.48% the period before.
Shareholding
As of 2026-06-30
- Promoter10.46%
- Public89.54%
6,865 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.38× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — GSM · GSM 0. Trading may carry price bands, periodic call auction or higher margins.
- Promoter holding fell 3.34 percentage points to 10.46% in the latest disclosure.
Peer comparison
Trading · ranked #345 of 666 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Adani Enterprises Limited | ₹3,96,659 Cr | 24.35 | 4.87 | 3.42% | 9.3% |
| Avenue Supermarts Limited | ₹2,52,648 Cr | 383.94 | 10.32 | 12.14% | 4.32% |
| Trent Ltd. | ₹1,59,927 Cr | 92.65 | 22.9 | 24.62% | 8.57% |
| FSN E-Commerce Ventures Ltd. | ₹95,580 Cr | 1236.11 | 66.46 | 13.87% | 1.99% |
| Vishal Mega Mart Limited | ₹50,539 Cr | 56.78 | 6.81 | 11.32% | 6.61% |
| Premier Energies Limited | ₹44,610 Cr | 29.55 | 10.36 | 35.05% | 19.3% |
| Aegis Logistics Limited | ₹43,850 Cr | 106.87 | 7.24 | 14.83% | 10.78% |
| Aditya Infotech Limited | ₹38,417 Cr | 226.85 | 20.46 | 19.61% | 8.72% |
| Redington Limited | ₹24,309 Cr | 15.27 | 2.39 | 14.67% | 1.25% |
| Honasa Consumer Limited | ₹14,510 Cr | 209.37 | 10.28 | 14.16% | 8.36% |
| Venmax Drugs & Pharmaceuticals Ltd.(this company) | ₹23 Cr | 92.67 | 1.6 | 1.76% | 2.49% |
AI analysis
AI-generated · google/gemini-2.5-flashVenmax Drugs & Pharmaceuticals Ltd. is listed on the Indian markets with a market capitalization of Rs 20 Cr. The company's revenue for the last fiscal year was Rs 1.86 Cr.
Positives
- +The debt-to-equity ratio is low at 0.11.
- +The profit margin is high at 249.4%.
- +Return on Equity (ROE) is significantly high at 175.8%.
Negatives
- −Sales have been inconsistent, with quarterly revenue at Rs 3.94 Cr in Mar 2026.
- −The company experienced a loss per share of -Rs 0.02 in Mar 2025.
- −Promoter holding is low at 10.4639%.
- −Return on Capital Employed (ROCE) is low at 1.9166%.
- −The company is currently under GSM surveillance.
Financial Performance
The company reported revenue of Rs 1.86 Cr for the last fiscal year. Net profit in Mar 2025 was -Rs 0.0105 Cr. Annual EPS has fluctuated, from -Rs 0.31 in Mar 2021 to Rs 0.12 in Mar 2024, and then to -Rs 0.02 in Mar 2025. Quarterly revenue was Rs 3.94 Cr and net profit was Rs 0.11 Cr in Mar 2026.
Profitability & Returns
Venmax Drugs & Pharmaceuticals Ltd. reported a profit margin of 249.4%. The Return on Equity (ROE) stands at 175.8%, while the Return on Capital Employed (ROCE) is 1.9166%.
Balance Sheet
The company's debt-to-equity ratio is 0.11, indicating a low level of debt relative to equity. The book value per share is Rs 12.18.
Ownership & Pledges
As of June 30, 2026, promoter holding in Venmax Drugs & Pharmaceuticals Ltd. was 10.4639%. Public shareholding was 89.5361%. There has been no reported pledging of promoter shares.
Regulatory & Surveillance
Venmax Drugs & Pharmaceuticals Ltd. is currently under GSM surveillance, specifically 'GSM 0', due to various measures, which include 'GSM'.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Venmax Drugs & Pharmaceuticals Ltd.share price & fundamentals